Risk Factors and Biomarkers for Post-tuberculosis Lung Damage

Peking University Third Hospital400 enrolled

Overview

This prospective study aims to determine the incidence of Post-tuberculosis lung damage (PTLD), examine trends in the changes in lung function, and investigate the impact of smoking and other factors on respiratory symptoms, lung function, and chest CT findings, which will aid in the development of prognostic and therapeutic strategies for PTLD.

Introduction: Post-tuberculosis lung damage (PTLD) refers to residual pulmonary impairment following the completion of tuberculosis (TB) treatment, characterized by persistent respiratory symptoms and abnormal pulmonary function. The risk factors and biomarkers for PTLD have been scarcely investigated. Additionally, it remains unclear whether and to what extent cigarette smoking affects PTLD in patients with TB. Methods and analysis: This prospective observational study will enroll 400 adult male ever-smoker or never-smoker patients aged 25-60 years, with newly confirmed active TB between 2022 and 2024 from the Department of Respiratory and Critical Care Medicine at Peking University Third Hospital and the Tuberculosis Department at Beijing Geriatric Hospital. Baseline data (age, smoking history, and smoking pack-years), clinical symptoms, lung functions, and chest CT (computed tomography) findings will be prospectively collected. Respiratory questionnaires, lung function measurements, and chest CT examinations will be completed during follow-up visits at 6 months after the initiation of TB treatment, immediately at the completion of TB treatment, and at 1 year, 2 years, and 3 years after the completion of TB treatment. Peripheral blood samples will be obtained at baseline to measure inflammatory mediators and cytokines in serum. The collected data will be analyzed to determine the incidence of and factors/biomarkers for PTLD after TB treatment.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Pulmonary TB

Interventions

no interventionOTHER

no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.

Eligibility

Sex: MALEMin age: 25 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: Male patients aged 25-60 years newly diagnosed with active pulmonary TB. Exclusion Criteria: 1. patients with positive sputum smear or TB culture results; 2. human immunodeficiency virus-positive patients; 3. patients infected with multidrug-resistant TB; 4. patients with malignant neoplasms (e.g., lung cancer) or severe cardiovascular and cerebrovascular diseases; 5. non-compliant patients who were unable to complete the lung function tests; 6. patients without lung parenchymal destruction (such as tuberculous pleurisy). -

Locations (2)

Peking University Third Hospital

Beijing, China

RECRUITING

Beijing Geriatric Hospital

Beijing, China

RECRUITING

Outcomes

Primary Outcomes

lung function

Forced expiratory volume (FEV1, l/min), and forced vital capacity (FVC,l/min) are the important parameters in lung function. FEV1/FVC, diffusing capacity for carbon monoxide (DLCO), and other indicators, will also be observed during follow-up.

Time frame: half a year, 1 year, 2 year, and 3-year follow-up

Secondary Outcomes

Absorption of TB lesions on lung CT scans after TB treatment

Chest CT images will be interpreted by a respiratory physician and a radiologist. Parenchymal and airway lesions detected on CT scans will be recorded

Time frame: half a year, 1 year, 2 year, and 3year follow-up

Central Contacts

Xiaoyan Gai, MD

CONTACT

13522708870 gxy81wfl79@163.com

Sun

CONTACT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.